The phenotype change in SCLC seems to be associated with retinoblastoma-1 (RB-1) and TP-53 genes inactivation and loss of ROS1-fusion expression and is associated with less sensitivity to platinum-etoposide chemotherapy [25]. Here, ROS1 is linked to small cell lung carcinoma.